Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
Abstract Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid beta (Aβ)42/Aβ40 could predict continuous values...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.12405 |
| _version_ | 1827977123044786176 |
|---|---|
| author | Julie K. Wisch Brian A. Gordon Anna H. Boerwinkle Patrick H. Luckett James G. Bollinger Vitaliy Ovod Yan Li Rachel L. Henson Tim West Mathew R. Meyer Kristopher M. Kirmess Tammie L.S. Benzinger Anne M. Fagan John C. Morris Randall J. Bateman Beau M. Ances Suzanne E. Schindler |
| author_facet | Julie K. Wisch Brian A. Gordon Anna H. Boerwinkle Patrick H. Luckett James G. Bollinger Vitaliy Ovod Yan Li Rachel L. Henson Tim West Mathew R. Meyer Kristopher M. Kirmess Tammie L.S. Benzinger Anne M. Fagan John C. Morris Randall J. Bateman Beau M. Ances Suzanne E. Schindler |
| author_sort | Julie K. Wisch |
| collection | DOAJ |
| description | Abstract Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid beta (Aβ)42/Aβ40 could predict continuous values for amyloid PET. Methods CSF Aβ42 and Aβ40 were measured with automated immunoassays. Plasma Aβ42 and Aβ40 were measured with an immunoprecipitation–mass spectrometry assay. Amyloid PET was performed with Pittsburgh compound B (PiB). The continuous relationships of CSF and plasma Aβ42/Aβ40 with amyloid PET burden were modeled. Results Most participants were cognitively normal (427 of 491 [87%]) and the mean age was 69.0 ± 8.8 years. CSF Aβ42/Aβ40 predicted amyloid PET burden until a relatively high level of amyloid accumulation (69.8 Centiloids), whereas plasma Aβ42/Aβ40 predicted amyloid PET burden until a lower level (33.4 Centiloids). Discussion CSF Aβ42/Aβ40 predicts the continuous level of amyloid plaque burden over a wider range than plasma Aβ42/Aβ40 and may be useful in AD staging. Highlights Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/Aβ40 predicts continuous amyloid positron emission tomography (PET) values up to a relatively high burden. Plasma Aβ42/Aβ40 is a comparatively dichotomous measure of brain amyloidosis. Models can predict regional amyloid PET burden based on CSF Aβ42/Aβ40. CSF Aβ42/Aβ40 may be useful in staging AD. |
| first_indexed | 2024-04-09T21:00:09Z |
| format | Article |
| id | doaj.art-d35aeb97748f4861a204b2e53b510cbe |
| institution | Directory Open Access Journal |
| issn | 2352-8729 |
| language | English |
| last_indexed | 2024-04-09T21:00:09Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj.art-d35aeb97748f4861a204b2e53b510cbe2023-03-29T11:42:33ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292023-01-01151n/an/a10.1002/dad2.12405Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40Julie K. Wisch0Brian A. Gordon1Anna H. Boerwinkle2Patrick H. Luckett3James G. Bollinger4Vitaliy Ovod5Yan Li6Rachel L. Henson7Tim West8Mathew R. Meyer9Kristopher M. Kirmess10Tammie L.S. Benzinger11Anne M. Fagan12John C. Morris13Randall J. Bateman14Beau M. Ances15Suzanne E. Schindler16Department of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Radiology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Radiology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USAC2N Diagnostics St. Louis Missouri USAC2N Diagnostics St. Louis Missouri USAC2N Diagnostics St. Louis Missouri USADepartment of Radiology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USADepartment of Neurology Washington University in Saint Louis St. Louis Missouri USAAbstract Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid beta (Aβ)42/Aβ40 could predict continuous values for amyloid PET. Methods CSF Aβ42 and Aβ40 were measured with automated immunoassays. Plasma Aβ42 and Aβ40 were measured with an immunoprecipitation–mass spectrometry assay. Amyloid PET was performed with Pittsburgh compound B (PiB). The continuous relationships of CSF and plasma Aβ42/Aβ40 with amyloid PET burden were modeled. Results Most participants were cognitively normal (427 of 491 [87%]) and the mean age was 69.0 ± 8.8 years. CSF Aβ42/Aβ40 predicted amyloid PET burden until a relatively high level of amyloid accumulation (69.8 Centiloids), whereas plasma Aβ42/Aβ40 predicted amyloid PET burden until a lower level (33.4 Centiloids). Discussion CSF Aβ42/Aβ40 predicts the continuous level of amyloid plaque burden over a wider range than plasma Aβ42/Aβ40 and may be useful in AD staging. Highlights Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/Aβ40 predicts continuous amyloid positron emission tomography (PET) values up to a relatively high burden. Plasma Aβ42/Aβ40 is a comparatively dichotomous measure of brain amyloidosis. Models can predict regional amyloid PET burden based on CSF Aβ42/Aβ40. CSF Aβ42/Aβ40 may be useful in staging AD.https://doi.org/10.1002/dad2.12405biomarker concordanceCSF Aβ42/Aβ40machine learningPETplasma Aβ42/Aβ40 |
| spellingShingle | Julie K. Wisch Brian A. Gordon Anna H. Boerwinkle Patrick H. Luckett James G. Bollinger Vitaliy Ovod Yan Li Rachel L. Henson Tim West Mathew R. Meyer Kristopher M. Kirmess Tammie L.S. Benzinger Anne M. Fagan John C. Morris Randall J. Bateman Beau M. Ances Suzanne E. Schindler Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring biomarker concordance CSF Aβ42/Aβ40 machine learning PET plasma Aβ42/Aβ40 |
| title | Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 |
| title_full | Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 |
| title_fullStr | Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 |
| title_full_unstemmed | Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 |
| title_short | Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 |
| title_sort | predicting continuous amyloid pet values with csf and plasma aβ42 aβ40 |
| topic | biomarker concordance CSF Aβ42/Aβ40 machine learning PET plasma Aβ42/Aβ40 |
| url | https://doi.org/10.1002/dad2.12405 |
| work_keys_str_mv | AT juliekwisch predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT brianagordon predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT annahboerwinkle predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT patrickhluckett predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT jamesgbollinger predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT vitaliyovod predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT yanli predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT rachellhenson predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT timwest predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT mathewrmeyer predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT kristophermkirmess predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT tammielsbenzinger predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT annemfagan predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT johncmorris predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT randalljbateman predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT beaumances predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 AT suzanneeschindler predictingcontinuousamyloidpetvalueswithcsfandplasmaab42ab40 |